US And European 3PL Integration Will Advance Pharmaceutical Networks

AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Published
06 Aug 24
Updated
31 Jul 25
AnalystConsensusTarget's Fair Value
US$329.07
12.4% undervalued intrinsic discount
31 Jul
US$288.35
Loading
1Y
19.5%
7D
0.8%

Author's Valuation

US$329.1

12.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 8.19%

Shared on30 Apr 25
Fair value Increased 0.84%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Increased 0.80%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Increased 3.73%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.38%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 2.88%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 0.55%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.